Exelixis, Inc. (NASDAQ:EXEL) went up by 2.73% from its latest closing price when compared to the 1-year high value of $27.80 and move down -25.11%, while EXEL stocks collected 2.68% of gains with the last five trading sessions. Press Release reported on 08/24/20 that Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX(R) (cabozantinib) in Combination With Opdivo(R) (nivolumab) for Advanced Renal Cell Carcinoma
Exelixis, Inc. (NASDAQ:EXEL) Worth an Investment?
Exelixis, Inc. (NASDAQ: EXEL) scored price to earnings ratio above its average ratio, recording 24.94 times of increase in earnings at the present.
EXEL Market Performance
EXEL stocks went up by 2.68% for the week, with the monthly drop of -3.77% and a quarterly performance of -8.45%, while its annual performance rate touched 11.94%. The simple moving average for the period of the last 20 days is -0.23% for EXEL stocks with the simple moving average of 7.25% for the last 200 days.
Analysts’ Opinion on Exelixis, Inc. (NASDAQ:EXEL)
Many brokerage firms have already submitted their reports for EXEL stocks, with Barclays repeating the rating for EXEL shares by setting it to “Overweight”. The predicted price for EXEL socks in the upcoming period according to Barclays is $26 based on the research report published on March 4, 2020.
SunTrust, on the other hand, stated in their research note that they expect to see EXEL stock at the price of $31. The rating they have provided for EXEL stocks is “Buy” according to the report published on January 13, 2020.
BofA/Merrill gave “Buy” rating to EXEL stocks, setting the target price at $22 in the report published on November 13, 2019.
EXEL Stocks -4.73% Far from 50 Day Moving Average
After a stumble in the market that brought EXEL to its low price for the period of the last 52 weeks, Exelixis, Inc. was unable to take a rebound, for now settling with -20.07% of loss for the given period.
The stock volatility was left at 3.04%, however, within the period of a single month, the volatility rate increased by 2.84%, while the shares sank at the distance of -6.21% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -8.11% lower at the present time.
In the course of the last 5 trading sessions, EXEL went up by +2.68%, which changed the moving average for the period of 200 days to the total of +35.74% of gains for the stock in comparison to the 20-day moving average settled at $22.20. In addition, Exelixis, Inc. saw 26.11% in overturn over the period of a single year with a tendency to cut further gains.
EXEL Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Exelixis, Inc. (EXEL), starting from Haley Patrick J., who sold 3,151 shares at the price of $25.36 back on Jul 20. After this action, Rushing now owns 112,189 shares of Exelixis, Inc., valued at $79,909 with the latest closing price.
Lamb Peter, the EVP, Scientific Strategy & CSO of Exelixis, Inc., sold 26,000 shares at the value of $22.56 during a trade that took place back on Jun 08, which means that Lamb Peter is holding 126,531 shares at the value of $586,560 based on the most recent closing price.
EXEL Stock Fundamentals
The current profitability levels are settled at +38.18 for the present operating margin and +96.58 for gross margin. The net margin for Exelixis, Inc. stands at +33.17. Total capital return value is set at 24.31, while invested capital returns managed to touch 21.16. Equity return holds the value 16.40%, with 14.70% for asset returns.
Based on Exelixis, Inc. (EXEL), the company’s capital structure generated 3.01 points for debt to equity in total, while total debt to capital is set at the value of 2.92.
The value for Enterprise to Sales is 4.71 with debt to enterprise value settled at 0.01. The receivables turnover for Exelixis, Inc. is 6.47 with the total asset turnover at the value of 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.08.